ACT-335827
ACT-335827 is a selective, orally active, brain-penetrant orexin type 1 receptor antagonist. ACT-33582 acts on OXR1 and OXR2 with IC50 values of 6 nM and 417 nM, respectively. ACT-33582 can be used in studies related to neurological disorders[1].
Product Specifications
CAS Number
1354039-86-3
UNSPSC
12352005
Target
Orexin Receptor (OX Receptor)
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/act-335827.html
Purity
98.0
Solubility
DMSO : 51.864 mg/mL (ultrasonic) |Ethanol : 51.864 mg/mL (ultrasonic)
Smiles
COC1=C(OC)C=CC(C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2[C@H](C4=CC=CC=C4)C(NC(C)C)=O)=C1
Molecular Formula
C31H38N2O5
Molecular Weight
518.64
References & Citations
[1]Michel A Steiner, et al. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem. 2013 Jun;8 (6) :898-903.|[2]Michel A Steiner, et al. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol. 2013 Dec 30;4:165.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
OX1 Receptor; OX2 Receptor
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0522105 3x 1.0 µg
CT45B1P sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Sign In for Pricing
View Details 
